A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The study aim is to compare the pharmacodynamic effects (cardiovascular effects- primary
variable: Heart rate over 4 hours post dosing- ) after administration of BDP and formoterol
administered as CHF 1535 100/6 NEXThaler DPI or CHF1535 pMDI at two different dose levels.